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Hypertension is a major global health challenge, as it represents the main risk factor for
stroke and cardiovascular disease. It is a multifactorial clinical condition characterized
by high and sustained levels of blood pressure, likely resulting from a complex interplay
of endogenous and environmental factors. The gut microbiota has been strongly
supposed to be involved but its role in hypertension is still poorly understood. In
an attempt to fill this gap, here we characterized the microbial composition of fecal
samples from 48 hypertensive and 32 normotensive Brazilian individuals by next-
generation sequencing of the 16S rRNA gene. In addition, the cytokine production
of peripheral blood samples was investigated to build an immunological profile of
these individuals. We identified a dysbiosis of the intestinal microbiota in hypertensive
subjects, featured by reduced biodiversity and distinct bacterial signatures compared
with the normotensive counterpart. Along with a reduction in Bacteroidetes members,
hypertensive individuals were indeed mainly characterized by increased proportions
of Lactobacillus and Akkermansia while decreased relative abundances of well-known
butyrate-producing commensals, including Roseburia and Faecalibacterium within the
Lachnospiraceae and Ruminococcaceae families. We also observed an inflamed
immune profile in hypertensive individuals with an increase in TNF/IFN-γ ratio, and in
TNF and IL-6 production when compared to normotensive ones. Our work provides
the first evidence of association of hypertension with altered gut microbiota and
inflammation in a Brazilian population. While lending support to the existence of
potential microbial signatures of hypertension, likely to be robust to age and geography,
our findings point to largely neglected bacteria as potential contributors to intestinal
homeostasis loss and emphasize the high vulnerability of hypertensive individuals to
inflammation-related disorders.
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INTRODUCTION
Hypertension is a major global health challenge, as it represents
the main risk factor for stroke and cardiovascular disease,
the number one cause of death worldwide, as well as for
kidney disorders (Hillege et al., 2000; Mills et al., 2016; de
Oliveira et al., 2017). In Brazil, high blood pressure (HBP)
has reached 30% of the adult population, 5% in children and
adolescents, and 50% in elderly people (Picon et al., 2012;
Ministério da Saúde, 2013). The identification of the causes
of hypertension is still challenging but it is widely accepted
that its etiology is multifactorial, involving an intricate set
of endogenous and environmental factors contributing to its
onset and progression. To date, HBP values have indeed
been associated with over 50 genetic loci and metabolic
pathways (such as those involved in the renin–angiotensin–
aldosterone system) (Levy et al., 2009, 2017; Newton-Cheh
et al., 2009; International Consortium for Blood Pressure
Genome-Wide Association Studies et al., 2011; Kato et al.,
2011; Ganesh S. K. et al., 2013; Tragante et al., 2014; Menni
et al., 2015; Xu et al., 2015; Liu et al., 2016), as well
as with lifestyle habits, such as dietary salt intake, alcohol
consumption and lack of physical activity (Fuchs et al., 2001;
Karppanen and Mervaala, 2006).
The human gut microbiota, i.e., the large array of microbes
inhabiting our gastrointestinal tract, plays key roles for our
physiology, by producing a wide and diverse pool of bioactive
small molecules, including short-chain fatty acids (SCFAs, mainly
acetate, propionate, and butyrate), which strongly impact on
metabolic homeostasis, and regulate immune and nervous system
function (Turroni et al., 2018). Emerging evidence suggests a
role for the gut microbiota in various disorders, at both enteric
and systemic level, including cardiovascular disease (Gregory
et al., 2015; Lynch and Pedersen, 2016; Li et al., 2017; Yan
et al., 2017; Tang et al., 2019). Specifically, several studies in
hypertensive rat models have directly or indirectly emphasized
the relevance of the gut microbiota in the regulation of blood
pressure (Khalesi et al., 2014; Gómez-Guzmán et al., 2015; Mell
et al., 2015; Moghadamrad et al., 2015; Yang et al., 2015; Durgan
et al., 2016). Only more recently, a few papers have explored
the intestinal microbial alterations underlying hypertension,
especially in cohorts of Chinese and United States adult
individuals, providing a range of phylogenetic and functional
signatures, and advancing a possible causal role of the gut
microbiota dysbiosis in contributing to the pathogenesis of
hypertension (Li et al., 2017, 2019; Yan et al., 2017; Dan et al.,
2019; Sun et al., 2019).
In an attempt to further extend this knowledge, including
other geographic locations and expanding the age range, here
we characterized the fecal microbiota from 48 hypertensive and
32 normotensive Brazilian adult individuals, by next-generation
sequencing of the 16S rRNA gene. In addition, the cytokine
production of peripheral blood samples was investigated. While
corroborating previous evidence on the decrease of health-
promoting SCFA producers in hypertension, our findings unveil
minority microbiota components potentially linked to HBP,
along with an overall inflamed profile.
MATERIALS AND METHODS
Study Population
Study population consisted of 80 volunteers aged >25 years, all
resident in Governador Valadares, an urban municipality from
the state of Minas Gerais (Southeast Brazil) and an endemic
area for schistosomiasis. The subjects were participants of an
institution called Casa Unimed, where they regularly went (twice
a week) for exercise programs, lectures, community groups,
music education, measurement of blood pressure and blood
glucose tests, aimed at promoting health and preventing disease.
Health conditions were checked according to standard clinical
investigations and standard hematological and biochemical
parameters. All subjects enrolled in this study were non-
institutionalized and living in their own household.
The individuals were stratified into a control normotensive
group and a hypertensive group based on the reported HBP
(higher than 140 mmHg for systolic and 90 mmHg for diastolic)
(Sociedade Brasileira de Cardiologia/Sociedade Brasileira de
Hipertensão/Sociedade Brasileira de Nefrologia, 2010) taken
previously at the time of diagnosis, and use of antihypertensive
medication including diuretic drugs, such as hydrochlorothiazide
and furosemide, angiotensin II receptor antagonists, such as
losartan and valsartan, as well as adrenergic receptors antagonists
(beta blockers), such as propranolol and atenolol. Some of the
individuals used a combination of diuretics and other classes
of drugs. The criterion for including them in the study was
“reported and treated hypertension for more than 10 years,”
which would characterize them as chronic patients with HBP.
The control subjects were those with no report of HBP.
General exclusion criteria were: infections, acute or chronic
inflammation, Schistosoma mansoni infection, autoimmune
diseases, undernourishment, anemia, leucopoenia, mood
disorders, neurodegenerative diseases, neoplasia, and use
of hormones (steroids) and drugs in the previous 2 weeks
(alcohol, antidepressants, immunosuppressants, anticoagulants,
antibiotics). Written informed consent was obtained from each
participant, prior to inclusion in our investigations. Fecal and
blood samples were collected from consenting participants
over a period of 2 weeks in February 2014. Blood samples were
immediately processed for peripheral blood mononuclear cell
(PBMC) separation as described below, and stored along with the
fecal samples at−80◦C until use. The fecal samples were used for
both microbiota analysis and parasitological exams. S. mansoni
infection was assessed by Kato–Katz parasitological method with
quantitative S. mansoni egg counts, using two slides prepared
from three stool samples. Twenty-four hour dietary recalls were
conducted for each enrolled subject over 3 days. We used the
standard method in nutritional science of sampling 2 week days
and 1 weekend day in an attempt to fully account for dietary
habits and fluctuations. Records were analyzed using TACO
(Brazilian table of food composition) (Universidade Estadual
De Campinas – Núcleo de Estudos e Pesquisas em Alimentac˛ão
NEPA – UNICAMP, 2006), and the caloric contributions of
the main macronutrient groups were calculated. This work was
approved by the Ethical Committee of Universidade Federal de
Minas Gerais (UFMG) as well as the National Research Ethics
Committee (CONEP) of Brazil.
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Microbial DNA Extraction From Feces
Total microbial DNA was extracted using the QIAamp DNA
Stool Mini Kit (QIAGEN, Hilden, Germany) with a modified
protocol (Yu and Morrison, 2004). Briefly, 250 mg of feces
were suspended in 1 ml of lysis buffer (500 mM NaCl,
50 mM Tris–HCl pH 8, 50 mM EDTA, 4% SDS). Four 3-
mm glass beads and 0.5 g of 0.1-mm zirconia beads (BioSpec
Products, Bartlesville, OK, United States) were added, and
samples were treated in FastPrep (MP Biomedicals, Irvine,
CA, United States) at 5.5 movements/sec for 1 min, repeated
three times. Samples were heated at 95◦C for 15 min, then
centrifuged for 5 min at 14,000 rpm to pellet stool particles.
Two hundred and sixty microliters of 10 M ammonium acetate
were added to the supernatant, followed by 5-min incubation in
ice and centrifugation at 14,000 rpm for 10 min. One volume
of isopropanol was added to each sample and incubated in
ice for 30 min. Precipitated nucleic acids were collected by
centrifugation for 15 min at 14,000 rpm and washed with 70%
ethanol. Pellets were suspended in 100 µl of TE buffer and treated
with 2 µl of DNase-free RNase (10 mg/ml) at 37◦C for 15 min.
Protein removal by proteinase K treatment and DNA purification
with QIAamp Mini Spin columns were performed following
the manufacturer’s instructions. DNA concentration and quality
were evaluated using NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, United States).
16S rRNA Gene Sequencing and Data
Processing
For each sample, the V3-V4 hypervariable region of the 16S
rRNA gene was amplified using the 341F and 805R primers
with added Illumina adapter overhang sequences as previously
described (Turroni et al., 2017). The resulting amplicons
of approximately 460 bp were cleaned up with Agencourt
AMPure XP magnetic beads (Beckman Coulter, Brea, CA,
United States). Indexed libraries were prepared by limited-
cycle PCR using Nextera technology and further cleaned up
as described above. Final libraries were pooled at equimolar
concentrations, denatured with 0.2 N NaOH and diluted to
8 pM with a 20% PhiX control. Sequencing was performed
on Illumina MiSeq platform using a 2 × 300 bp paired end
protocol according to the manufacturer’s instructions (Illumina,
San Diego, CA, United States).
Raw sequences were processed using a pipeline combining
PANDAseq (Masella et al., 2012) and QIIME (Caporaso et al.,
2010). Quality-filtered reads were binned into Operational
Taxonomic Units (OTUs) at 97% similarity threshold using
UCLUST (Edgar, 2010). Taxonomy was assigned using the
RDP classifier against Greengenes database (May 2013 release).
All singleton OTUs were discarded. Alpha rarefaction was
performed using the Faith’s phylogenetic diversity, observed
OTUs and Shannon index metrics. Beta diversity was estimated
by computing weighted and unweighted UniFrac distances,
which were used as input for Principal Coordinates Analysis
(PCoA). OTUs assigned to genera of interest whose species
were unclassified, were subjected to BLAST analysis (Altschul
et al., 1990). Sequencing reads were deposited in the MG-RAST
database (project ID, mgp84730). All statistical analysis was
performed in R 3.3.2. UniFrac distances were plotted by the
vegan package, and data separation in the PCoA was tested
using a permutation test with pseudo-F ratios (function Adonis
in vegan). Bacterial groups with the largest contribution to
the ordination space were found by using the function envfit
in vegan on the genus relative abundance and the weighted
UniFrac ordination. Linear Discriminant Analysis Effect Size
(LEfSe) algorithm with LDA score threshold of 2 (on a log10
scale) was applied after agglomerating data to genus and
species level (Segata et al., 2011). Significant differences in
alpha diversity and taxon relative abundances between groups
were assessed by Mann–Whitney U test. When appropriate,
p values were corrected for multiple comparisons using the
Benjamini–Hochberg method. A p value ≤ 0.05 was considered
as statistically significant, whereas a p value between 0.05 and 0.1
was considered a tendency.
Cytokine Measurements
PBMC Obtainment
Peripheral blood mononuclear cells (PBMCs) were isolated by
centrifugation (400 × g for 45 min at 18◦C) over Ficoll-
Hypaque gradient cushion (LMS Litton Biometries, Kensington,
MD, United States), as described by Gazzinelli et al. (1983).
After separation, PBMCs were washed in RPMI 1640 and
resuspended to 1 × 107 cells/ml. One hundred microliters of
PBMC suspension, containing 1 × 106 cells, were incubated for
6 days at 37◦C, in humidified incubator containing 5% CO2, in
24-well flat bottom plates, in the presence of 800 µl of RPMI
1640 medium, supplemented with 5% AB Rh-positive heat-
inactivated human serum (Sigma, St. Louis, MO, United States),
containing 3% of antibiotic/antimycotic solution, from the stock
mix containing 10,000 IU of penicillin, 10 mg of streptomycin,
and 25 µg of amphotericin B per ml (Gibco-BRL, Grand Island,
NY, United States). Afterward, the culture supernatants were
collected and immediately frozen at−80◦C, and kept stored until
flow cytometric cytokine measurements.
Cytokine Beads Array
Quantitative cytokine analysis was performed using the
Cytometric Bead Array method (Human Cytokine Flex Set,
Becton Dickinson, Pharmingen, San Diego, CA, United States)
for simultaneous measurement of IFN-γ, TNF-α, IL-17A, IL-6,
IL-10, IL-4, and IL-2, as recommended by the manufacturer.
Twenty-five microliters of supernatant from PBMC cell
cultures were incubated with a mixture of beads coated with
capture antibodies specific for each cytokine, labeled with
distinct red fluorescence intensities. After incubation and wash
steps, the system was incubated with 17 µl of phycoerythrin
(PE)-labeled anti-cytokine antibody. After washings and flow
cytometric acquisition, the relative fluorescence intensity for
each bead was determined, and the results expressed as
pg/ml for each cytokine, according to the standard curves.
A total of 400 events/cytokine-specific-bead were acquired on a
FACSVersermTM Bioanalyzer (Becton Dickinson). Data analysis
was performed using the FCAP array software (Soft Flow, Inc.,
St. Louis Park, MN, United States).
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Cytokine Data Analysis
In the present study, one of the strategies used was an
innovative model to analyze the immune response, referred to
as functional cytokine signature. This model was designed to
convert quantitative cytokine measurements into a categorical
analysis of low and high cytokine producers as previously
proposed by Luiza-Silva et al. (2011). This approach is able to
detect subtle differences not detectable by conventional statistical
analysis. Briefly, this categorical approach first converts the
continuous cytokine measurements expressed in pg/ml into
categorical variables, referred to as “Low” or “High” cytokine
levels, taking the global median value as a specific cut-off edge
for each cytokine. The use of such a global median cut-off for
each cytokine allows for multiple comparative analyses between
groups using the same criteria. Following data categorization,
gray-scale diagrams were assembled to compile the cytokine
pattern (columns) for each volunteer (rows). Column statistics
was run for each diagram to calculate the frequency of
“High Cytokine Producers” for each subject group. Next, the
frequencies of “High Cytokine Producers” were ordered in an
ascendant manner to create the ascendant curves referred to
as “cytokine signatures.” From each cytokine signature curve,
the attributes with frequencies greater than 50% were selected
for profile analysis. Then, cytokine ratios were calculated to
evaluate the immunological profile for each subject group.
The non-parametric Mann–Whitney U test was used to assess
significant differences. A p value < 0.05 was considered as
statistically significant.
Another innovative strategy adopted was the inflammatory
score, calculated according to previous studies (Duncan et al.,
2003; Recasens et al., 2005; Biagi et al., 2010). Specifically, the
inflammatory score was calculated based on three inflammatory
cytokines, whose production was assessed as relevant in the HBP
group according to the cytokine ratio (Figure 3) and signature
analysis (Figure 4). To obtain such a score, the global median
for each selected cytokine was calculated, and every value greater
than the median gave 1 point to the subject. The inflammatory
score ranged from 0 to 3. Scores 0 and 1 were categorized as “Not
Inflamed” and scores 2 and 3 were categorized as “Inflamed.”
Finally, the frequency of inflammatory score category for each
group was calculated.
RESULTS
Study Population
Eighty subjects (21 males and 59 females) aged 26–87 years (mean
64.5), were recruited for the present study. This population was
stratified according to the presence of reported HBP (higher
than 140 mmHg for systolic and 90 mmHg for diastolic)
(Sociedade Brasileira de Cardiologia/Sociedade Brasileira de
Hipertensão/Sociedade Brasileira de Nefrologia, 2010) and the
chronic use of antihypertensive medication that kept their HBP
under control. Forty-eight subjects had HBP (HBP group) while
32 had not (control). The demographic data of individuals are
summarized in Table 1. No differences were found in age or
gender distribution between the two groups.
Intestinal Microbiota Diversity Is Altered
in Hypertensive Subjects
Fecal samples were collected from the 80 subjects recruited
in Governador Valadares, and the V3-V4 region of the
bacterial 16S rDNA was sequenced. A total of 3,790,002
high-quality reads (mean per subject, 47,375; range, 3,745–
1,50,790) were obtained and analyzed. Reads were clustered
into 24,575 OTUs at 97% identity. Rarefaction curves
obtained with phylogenetic diversity and OTU count did
not reach saturation while the Shannon index for biodiversity
plateaued at a sequence depth of about 1000 read counts
(Supplementary Figure S1). According to this index (a
combined parameter of richness and evenness), alpha diversity
values were lower in the HBP group compared to normotensive
controls (p = 0.04, Mann–Whitney U test; Figure 1A).
Furthermore, HBP and control groups significantly, even
if only barely, segregated according to weighted UniFrac
distances (p = 0.04, R2 = 0.02, permutation test with pseudo-
F ratios; Figure 1B). Specifically, the PCo1 axis, which
accounted for 43% of the total variance in the dataset, was
negatively associated with the presence of HBP (p = 0.03,
Mann–Whitney U test).
Hypertensive Subjects Show a Gut
Microbiota Dysbiosis
At phylum level, the HBP-related gut microbiota tended
to show a contraction of Bacteroidetes (mean relative
abundance, 4.96% vs. controls, 8.97%; p = 0.03, FDR-
adjusted p = 0.1, Mann–Whitney U test), resulting in
a significantly increased Firmicutes/Bacteroidetes ratio
in hypertensive vs. normotensive subjects (p = 0.03)
(Supplementary Figure S2).
In order to identify the bacterial genera responsible for
the separation between the microbiota structure of HBP and
control subjects, relative abundance vectors with a statistically
significant contribution were identified and overlaid onto
the ordination space based on weighted UniFrac distances
of Figure 1B (p < 0.05, permutational correlation test).
Interestingly, several microbial taxa were found to drive
the clustering pattern, i.e., Lactobacillus, Akkermansia,
Bifidobacterium, and unclassified Enterobacteriaceae, which
were associated with HBP, and well-known butyrate producers
of the Lachnospiraceae and Ruminococcaceae families,
including Roseburia, Coprococcus, Dorea, and Oscillospira,
which were associated with controls (Figures 2A,B). Most
of these genera were also identified as discriminating
according to LEfSe analysis (Figure 2C). These differences
are likely to be attributable to the species Roseburia faecis,
Faecalibacterium prausnitzii, Parabacteroides distasonis, and
unclassified species belonging to the genera Fusobacterium
and Coprobacillus, which were representative of normotensive
controls, and Lactobacillus salivarius, Bacteroides plebeius
and an unclassified species belonging to Eggerthella,
which were characteristic of hypertensive individuals
(p ≤ 0.05, FDR-adjusted p ≤ 0.1, Mann–Whitney U
test) (Supplementary Figure S3). According to BLAST,
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TABLE 1 | Demographic and health data of individuals from Casa Unimed in Governador Valadares, stratified by the presence of high blood pressure (HBP).
Data All subjects Control group HBP group p-value
N. 80 32 48 –
Male 21 7 14 0.6056*
Female 59 25 34
Age (mean ± SD) 64.5 ± 15.3 63.3 ± 15.0 65.3 ± 15.5 0.5611**
Age range 26–87 28–86 26–87
High Blood Pressure 48 0 48 –
*, Fisher’s exact test; **, Student’s t test.
FIGURE 1 | Comparison of the gut microbiota structure between hypertensive (HBP) and normotensive (control) subjects. (A) Alpha-diversity values were calculated
according to the following metrics: the Shannon index for biodiversity, phylogenetic diversity (PD) and OTU count. *, p = 0.04, Mann–Whitney U test. (B) Principal
Coordinates Analysis of the weighted UniFrac distances for HBP and control subjects. The two components explain 43 and 15% of the variance, respectively.
A significant separation was found between the two groups (p = 0.04, permutation test with pseudo-F ratios). Red, HBP subjects (n = 48); blue, controls (n = 32).
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FIGURE 2 | Intestinal microbial components driving the separation between hypertensive (HBP) and normotensive (control) subjects. (A) Genus-level relative
abundance vectors with statistically significant contribution to the ordination space (p < 0.05, permutational correlation test) were overlaid onto the PCoA plot of
weighted UniFrac distances (see Figure 1B). Triangles, centroids for each group (red, HBP; blue, control) with indication of standard errors on each coordinate axis.
*, unclassified OTU reported at higher taxonomic level. PCo1 was negatively associated with the presence of HBP while PCo2 correlated positively with age. (B) Bar
plots showing the relative abundance of the Lachnospiraceae family and the genera Coprococcus and Roseburia in HBP and control subjects. *p = 0.02; p = 0.04;
p = 0.003, respectively; Mann–Whitney U test. (C) Linear discriminant analysis (LDA) effect size (LEfSe) analysis. LDA scores indicate differentially represented genera
between groups (the logarithmic threshold for discriminative features was set to 2.0). *, unclassified OTU reported at higher taxonomic level.
Eggerthella, Fusobacterium and Coprobacillus OTUs showed
the highest percent identity with Eggerthella lenta (91%),
Fusobacterium (pseudo)periodonticum (99%), and Coprobacillus
cateniformis (95%), respectively. However, it should be
stressed that, given the known resolution limits of 16S
rRNA gene-based sequencing, these species-level results
must be interpreted with extreme caution, at least until
further information, through other approaches possibly
based on full-length 16S rRNA gene sequencing or shotgun
metagenomics, is available.
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The Gut Microbiota Dysbiosis in
Hypertensive Subjects Is Likely
Independent of Age and Macronutrient
Intake
Given the wide age range of volunteers, spanning young
adults and elderly, we investigated the impact of age on the
gut microbiota composition in our study cohort. According
to weighted UniFrac distances, age was not associated with
PCo1 (i.e., the axis along which HBP and control subjects
clustered significantly), suggesting that the intestinal microbial
dysbiosis in HBP may be independent of it (see Supplementary
Figure S4). It was instead shown to correlate with the second
axis of the PCoA plot, parallel to the relative abundance of
several bacterial taxa (Figure 2A), confirming previous (HBP-
independent) observations on the dynamics of the gut microbiota
during aging (Odamaki et al., 2016; Biagi et al., 2017). In
particular, higher age was found to be associated with higher
proportions of Oscillospira and especially Enterobacteriaceae,
already known to increase in the elderly in a sort of self-sustained
pro-inflammatory loop. On the other hand, as expected, lower
age was associated with increasing amounts of health-promoting
bifidobacteria, along with SCFA producers of the gut microbiota,
in particular Dorea and Ruminococcaceae members.
Furthermore, given the pivotal role of diet in shaping the gut
microbiota (Zmora et al., 2019), we evaluated the dietary habits
of volunteers through 3-day food frequency recalls. According
to our data, no differences in the proportion of macronutrients
between HBP and control individuals were observed (see
Supplementary Table S1).
Hypertensive Subjects Show an Overall
Inflammatory Cytokine Profile
In order to assess whether the hypertensive subjects also had
a different immunological profile compared to controls, the
cytometric bead array (CBA) method was used to evaluate
the production of IL-6, IFN-γ, TNF-α, IL-17A, and IL-10.
We excluded IL-4 and IL-2 from the analysis, because their
measurements were too low (median = 0 for both cytokines).
According to our findings, there were no differences in
the cytokine concentration between control and HBP groups
(p > 0.05, Mann–Whitney U test; Figure 3A). However, to
fully explore the possible contribution of these cytokines to the
immunological profile of our study groups, we calculated several
cytokine ratios, commonly used in immunological analysis
(Gómez et al., 2004; Coelho-dos-Reis et al., 2013; Tsurumi
et al., 2016; Medeiros et al., 2018), by creating a measure of
balance between cytokine profiles. Interestingly, an increased
TNF-α/IFN-γ ratio was found in HBP compared to the control
group (p = 0.02, Mann–Whitney U test; Figure 3B), suggesting
an overall inflammatory profile for HBP subjects. No difference
was detected for the other ratios (data not shown).
To further deepen the contribution of these cytokines,
individuals were stratified in carriers of either low or high
cytokine producers taking the global median of the cytokine
index as the cut-off (Figure 4; please see the section “Materials
and Methods” for the functional cytokine signature analysis),
as previously reported (Luiza-Silva et al., 2011; Campi-Azevedo
et al., 2012; Silveira-Nunes et al., 2017). When considering the
frequency of high cytokine producers, a relevant production (i.e.,
more than 50% of individuals were high producers) was only
found in the HBP group for TNF-α and IL-6 (Figure 4B).
Finally, to support the hypothesis of increased inflammation
in HBP subjects, an inflammatory score, based on three
inflammatory cytokines, whose production was assessed as
relevant in the HBP group according to the cytokine ratio
and signature analysis, i.e., IFN-γ, TNF-α, and IL-6 (please
see section “Materials and Methods”), was calculated. Subjects
were considered as inflamed for inflammatory scores of 2 and
3, and as non-inflamed for scores of 0 or 1. In this analysis
(Figure 5), we observed that more than half (50% as a cut-off)
of the individuals from the HBP group (54%) were categorized as
inflamed by inflammatory score, a result we did not observe in
the control group (47%).
DISCUSSION
Hypertension is a multifactorial clinical condition characterized
by high and sustained levels of blood pressure, likely resulting
from a complex interplay of endogenous and environmental
factors, including the gut microbiota (Mell et al., 2015;
Moghadamrad et al., 2015; Yang et al., 2015; Durgan et al., 2016;
Galla et al., 2017; Oyama and Node, 2019). Epidemiological
studies have shown that high levels of blood pressure are
widely associated with increased risk of fatal and non-
fatal cardiovascular events (Lewington et al., 2002; Williams
et al., 2008). Although research in the field has grown
considerably in recent years, the etiology of hypertension is
poorly understood and there is still limited evidence on the role
of the gut microbiota.
In an attempt to bridge these gaps, here we sequenced the
bacterial 16S rRNA gene of fecal samples from a cohort of 48
hypertensive and 32 normotensive Brazilian individuals, and
integrated the analysis with extensive immunological profiling.
Consistent with recent findings in Chinese and United States
cohorts (Li et al., 2017, 2019; Yan et al., 2017; Dan et al.,
2019; Sun et al., 2019), our study highlighted a dysbiosis of
the intestinal microbiota in hypertensive subjects, featured by
reduced biodiversity and distinct bacterial signatures compared
with the normotensive counterpart (see Supplementary Table S2
for a review of available studies on gut microbiota and
hypertension). Loss of microbial diversity is widely recognized as
a hallmark of unhealthy microbiota and so far has been reported
in a plethora of human disorders, including (but not limited
to) gastrointestinal, immune and metabolic ones (Sonnenburg
and Sonnenburg, 2014), thus likely to be part of a non-specific,
shared response to the disease. With regard to the taxonomic
structure, we found a higher Firmicutes/Bacteroidetes (F/B) ratio
in the gut microbiota of hypertensive individuals compared to
controls, resulting from a reduction in the relative proportion
of Bacteroidetes. Interestingly, also Yang et al. (2015) reported
an increased F/B ratio in a small group of hypertensive patients,
as well as in rat models of hypertension. Although still debated,
the F/B ratio has been widely used in the past as a marker
of an obesogenic microbiota, with high values being generally
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FIGURE 3 | Comparison of cytokine production in the supernatant of PBMCs between the high blood pressure group (HBP) and control group (Control). (A) The
bars represent the median and interquartile of the cytokine concentration (pg/ml), as determined by flow cytometry, for each study group. (B) The bars represent the
TNF/IFN-γ ratio. *, p = 0.02, Mann–Whitney U test.
associated with the consumption of high-fat low-fiber Western
diets and inflammation (Turnbaugh et al., 2009; Everard and
Cani, 2013; Trompette et al., 2014; Nakayama et al., 2017).
At the genus level, our results confirmed previous evidence on
the relative abundance decrease of several SCFA (mainly
butyrate) producers, generally recognized as beneficial
components of the human gut microbiota, including members
of the Lachnospiraceae and Ruminococcaceae families, such
as Roseburia and Faecalibacterium (Li et al., 2017, 2019; Yan
et al., 2017; Dan et al., 2019). Such alterations could therefore
represent robust dysbiotic microbial signatures, regardless
of geography and lifestyle. SCFAs are known to exert a key,
multifactorial role in human physiology, not only locally
but also at distant body sites, promoting the maintenance of
metabolic and immunological homeostasis (Koh et al., 2016).
In particular, they have been shown to regulate blood pressure
via the sensory receptors Olfr78 (Olfactory receptor 78) and
GPR41 (G protein-coupled receptor 41), acting in opposition
to one another (Pluznick, 2014), and exert relaxant effects
on resistance arteries (Mortensen et al., 1990), thus possibly
improving microcirculation. Furthermore, SCFAs are known to
have important anti-inflammatory effects (Vinolo et al., 2011;
Vieira et al., 2012; Chang et al., 2014; Iraporda et al., 2015; Park
et al., 2015; Yang and Zubcevic, 2017). Specifically, they are able
to inhibit the activation of NF-κB in immune cells by binding to
GPR43 and GPR41, thereby blocking inflammatory responses
and suppressing the production of TNF-α and IL-6. Butyrate also
suppresses inflammation by reducing IL-12 and increasing IL-10
expression (Säemann et al., 2000; Fukae et al., 2005; Tedelind
et al., 2007), and it promotes transcription of the Foxp3 gene,
inducing the production of regulatory T cells (Furusawa et al.,
2013). As thoroughly discussed by Million et al. (2018), butyrate
could represent the best functional marker of the healthy mature
anaerobic gut microbiota, and oxidative stress-sensitive butyrate-
producing commensals could serve as new instrumental targets
for the maintenance of a microbiota-immunity symbiotic loop
and the prevention of a series of local and systemic dysbiosis-
related disorders. It is also worth noting that Roseburia, one of
the main butyrate-producing microbes that were found to be
underrepresented in hypertension, also produces conjugated
linoleic acid, which has been shown to have anti-inflammatory
properties and potential blood pressure-lowering effects as well
(McIntosh et al., 2009; Neyrinck et al., 2012; Van den Abbeele
et al., 2013; Derrien and Veiga, 2017).
Interestingly, our study also led to the identification
of other bacteria deserving further investigation for their
possible role in hypertension, especially Lactobacillus (most
likely L. salivarius), Eggerthella and possibly B. plebeius,
which were found to be discriminating for hypertensive
individuals. While the literature is consistent in reporting
both Eggerthella and B. plebeius as potential pathogens for
cardiovascular disease, with the former already found to occur
at higher levels in patients with hypertension compared to
controls (Yan et al., 2017) and the latter being associated
with dyslipidemia (Liu et al., 2019), conflicting evidence is
available for lactobacilli. Some clinical trials in fact support
hypotensive effects for Lactobacillus species used as probiotics
(Upadrasta and Madempudi, 2016), but this genus and/or
certain species have also been found to be overabundant
in some inflammatory disorders, including obesity (Million
et al., 2012), coronary heart disease (Yamashita, 2017), and
heart failure (Kamo et al., 2017). In particular, the species
L. salivarius has recently been assigned to metagenomics linkage
groups enriched in the gut microbiome of individuals with
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FIGURE 4 | Cytokine signature analysis in hypertensive (HBP) and normotensive (control) individuals. (A) Establishing cut-off edges to categorize the subjects as
“Low” or “High” cytokine producers. The cytokine quantitative analysis was performed by flow cytometry using the Cytometric Bead Array as described in Methods.
The cut-off line was established as the global median value calculated for each cytokine, taking the whole dataset, including all subjects. The use of such a global
median cut-off for each cytokine subsidizes multiple comparative analyses between groups using the same criterion. The subjects were then categorized as “Low”
(white box) or “High” (black box) cytokine producers. (B) Assembling the ascendant cytokine signatures. Diagrams were assembled to compile the cytokine pattern
(columns) for each volunteer (lines). Column statistics was run for each diagram to calculate the frequency of “High Cytokine Producers” for each group of patients.
(C) The cytokine signature profiles. The frequencies of “High Cytokine Producers” were ordered in an ascendant manner to create the ascendant patterns referred to
as “cytokine signatures.” From each cytokine signature curve, the attributes with frequencies higher than 50% (i.e., more than half of the group are high cytokine
producers) were selected (dashed rectangle).
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FIGURE 5 | Inflammatory score in hypertensive (HBP) and normotensive (control) subjects. The inflammatory score was calculated based on three inflammatory
cytokines, whose production was assessed as relevant in the HBP group according to the cytokine ratio and signature analysis, i.e., IFN-γ, TNF, and IL-6. The global
median for each selected cytokine was calculated, and every value greater than the median gave 1 point to the subject. The sum of the points for each subject
defined its Inflammatory Score. The inflammatory score ranged from 0 to 3. Scores 0 and 1 were categorized as Not Inflamed and scores 2 and 3 were categorized
as Inflamed. The frequency of inflammatory score category for each group was calculated. The bars represent the frequency of Inflamed (score 2–3) and Not
Inflamed (score 0–1) subjects in control (blue) and HBP group (red).
atherosclerotic cardiovascular disease (Jie et al., 2017), thus
opening fascinating perspectives on the possible use of this
species as a non-invasive biomarker for blood pressure-related
diseases. It is also worth noting that we found an association
between hypertension and the mucin degrader Akkermansia.
Although this microorganism is generally associated with
improved metabolic profile (Everard et al., 2013), it has recently
been reported to show greater abundance in hypertensive
Chinese subjects (Dan et al., 2019) and exacerbate inflammation
during infections by disturbing the mucus layer homeostasis
(Ganesh B. P. et al., 2013). Recent evidence in human PBMCs and
mice also indicates that Akkermansia promotes Th1 lymphocyte
differentiation (Cekanaviciute et al., 2017). It is thus tempting
to speculate that this microbiota member may play a role in
hypertension, by sustaining and contributing to an overall pro-
inflammatory environment.
Consistent with our hypothesis, we observed an inflamed
immune profile in hypertensive individuals. Chronic
inflammation is one of the biological mechanisms most
commonly associated with hypertension (Blake et al., 2003;
Cevenini et al., 2010; Chung et al., 2010; Singh and Newman,
2011; Youn et al., 2013; De Miguel et al., 2015). Bautista et al.
(2005) demonstrated that the plasma levels of inflammatory
cytokines, such as C-reactive protein, IL-6, and TNF-α,
positively correlated with blood pressure in humans. In
agreement with those findings, our results revealed an increase
of type 1 cytokines, with an increased TNF/IFN-γ ratio, in
hypertensive individuals when compared to normotensive
ones, thus strengthening the hypothesis that inflammation
plays an important role in hypertension. Specifically, according
to our ascending profile analysis, TNF and IL-6 were the
main cytokines responsible for the leukocyte immune profile
of hypertensive individuals, and 50% of them had high
inflammatory scores. The association of elevated levels of
TNF-α with hypertension has been demonstrated through
pharmacological and genetic approaches in experimental
models, including angiotensin II-induced hypertension,
lupus, metabolic syndrome and preeclampsia (Zinman
et al., 1999; Ito et al., 2001; Guzik et al., 2007; Venegas-
Pont et al., 2010; Ramseyer and Garvin, 2013). The IL-6 levels
are also frequently elevated under hypertensive conditions.
In particular, studies have shown that IL-6 is essential for
the development of angiotensin II-induced hypertension and
that the activation of the STAT3/JAK pathway by IL-6 plays
a key role in the disease (Brands et al., 2010). In addition,
human studies confirmed increased plasma levels of IL-6
in response to acute angiotensin II infusion, and also in
hypertensive patients (Furuya et al., 2010; Chamarthi et al., 2011;
De Miguel et al., 2015).
In summary, despite the small sample size, our work provides,
to the best of our knowledge, the first evidence of an association
of hypertension with altered gut microbiota and inflammation in
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a Brazilian population. While lending support to the existence
of microbial signatures of hypertension, possibly robust to
age and geography, and stressing the need for species-level
analysis in future microbiome-based studies, our findings point
to bacteria widely neglected to date as potential contributors
to the loss of intestinal homeostasis, and emphasize the
high vulnerability of hypertensive individuals to inflammation-
related disorders. Future studies in independent and much
larger cohorts, also through other methods, including culture-
dependent ones, are encouraged to assess alterations in the
microbiota-host co-metabolic networks and their contribution to
hypertension and related complications. This information will be
instrumental to the design of rational nutritional interventions
aimed at correcting the gut dysbiosis and mitigating dysregulated
immune responses, for reduced incidence and severity of
chronic diseases.
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